Nexeos Bio Gets FDA Clearance to Begin Phase II/III Trial of NTX-1024
ReutersFeb 19, 2026 4:45 PM
Feb 19 (Reuters) - Nexeos Bio:
NEXEOS BIO ANNOUNCES FDA CLEARANCE OF IND APPLICATION TO PROCEED TO PHASE II/III TRIAL OF NTX-1024 IN VERNAL KERATOCONJUNCTIVITIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
New Fed Chair Warsh Takes Office: Major Shift in Monetary Policy? US Dollar Short-Term Rebound, 2026 Investment Strategy Analysis
TradingKey - At the start of 2026, global financial markets witnessed a major leadership change as U.S. President Trump officially nominated Kevin Warsh as the next Federal Reserve Chair. Pending Senate confirmation, he will succeed Jerome Powell this May to lead the world’s most influential central bank.TradingKey
11 hours ago
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.TradingKey
19 hours ago
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
Wed, Feb 18
